NASDAQ: GILD
Key Data Points
How to buy Gilead Sciences stock
Since it’s a publicly traded company, anyone can buy Gilead Sciences stock. Here’s a step-by-step guide on how to invest money in the pharmaceutical stock:
- Step 1: Open your brokerage account: Log in to your brokerage account where you handle your investments.
- Step 2: Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
- Step 3: Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Step 4: Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Step 5: Submit your order: Confirm the details and submit your buy order.
- Step 6: Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
Should I invest in Gilead Sciences?
Before investing in Gilead Sciences, you need to determine whether the biotech stock is a good fit for your portfolio. Here are some reasons why you might want to buy the stock:
- You believe Gilead can continue to develop innovative medicines and grow shareholder value.
- You want to invest in companies that pay a growing dividend.
- You’re excited by the company’s drug pipeline and believe it has some blockbusters under development.
- You want to invest in a pharmaceutical stock that’s not facing a near-term patent cliff (Gildead has no major loss of exclusivity until 2036).
- You want to invest in a financially strong biopharma company.
On the other hand, here are some factors that might lead you to reconsider investing in the company:
- You’re concerned about potential legislative changes that could hurt the profitability of pharmaceutical companies.
- You want to invest in an earlier-stage biotech company with more upside potential.
- You already own several other pharmaceutical stocks.
- You think rival biotech companies have better drug pipelines and growth prospects.
Is Gilead Sciences profitable?
Several factors can affect a company’s stock price in the short term. However, profitability tends to be the biggest factor driving a company’s ability to grow shareholder value over the long term.
Gilead Sciences is a very profitable company. Through the first nine months of 2025, the company generated $21.5 billion of revenue and $6.3 billion of net income. The company also generates strong cash flow, with $6.7 billion in operating cash flow and $6.3 billion in free cash flow produced during that period. This robust free cash flow allows the company to return money to shareholders ($1 billion of dividend payments and $435 million of share repurchases in the third quarter). It also supports Gilead’s strong cash-rich balance sheet (a $9.4 billion cash balance in late 2025).
The company’s robust profitability enables it to invest heavily in research and development (R&D) to discover and launch new treatments, while also returning cash to shareholders.
Does Gilead Sciences pay a dividend?
Yes, Gilead Sciences pays a dividend. As of late 2025, Gilead Sciences had paid a dividend every quarter since it initiated the payout in 2015. It has steadily increased its payment over the years, including by 2.6% in the first quarter of 2025.
Date | Stock Split
Type |
|---|---|
February 2001 | 2-for-1 |
March 2002 | 2-for-1 |
September
2004 | 2-for-1 |
June 2007 | 2-for-1 |
December 2012 | 2-for-1 |
Gilead Sciences’ share price had risen to an all-time high of $124.08 per share (split adjusted) in October 2025. If the share price continues to rise, Gilead might split its stock again to make shares more accessible to a wider range of investors.
Related investing topics
The bottom line on Gilead Sciences
Gilead Sciences stands out as a highly profitable pharmaceutical company with a strong balance sheet, no imminent loss of patent exclusivity, and a promising drug pipeline. These strengths put the company in an excellent position to grow shareholder value. For investors seeking stability, innovation, and long-term growth potential in the biopharma sector, Gilead Sciences is a compelling choice.
FAQ
About the Author
